NZ761430B2 - Cytokine conjugates for the treatment of proliferative and infectious diseases - Google Patents

Cytokine conjugates for the treatment of proliferative and infectious diseases Download PDF

Info

Publication number
NZ761430B2
NZ761430B2 NZ761430A NZ76143018A NZ761430B2 NZ 761430 B2 NZ761430 B2 NZ 761430B2 NZ 761430 A NZ761430 A NZ 761430A NZ 76143018 A NZ76143018 A NZ 76143018A NZ 761430 B2 NZ761430 B2 NZ 761430B2
Authority
NZ
New Zealand
Prior art keywords
polypeptide
modified
cell
cancer
seq
Prior art date
Application number
NZ761430A
Other versions
NZ761430A (en
Inventor
Carolina E Caffaro
Marcos Milla
Jerod Ptacin
Original Assignee
Synthorx Inc
Filing date
Publication date
Application filed by Synthorx Inc filed Critical Synthorx Inc
Priority claimed from PCT/US2018/045257 external-priority patent/WO2019028419A1/en
Publication of NZ761430A publication Critical patent/NZ761430A/en
Publication of NZ761430B2 publication Critical patent/NZ761430B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) comprising one or more unnatural amino acids for use in the treatment of one or more indications, such as cancer. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).

Claims (49)

1. A modified interleukin 2 (IL-2) polypeptide comprising at least one unnatural amino acid covalently attached to a conjugating moiety, wherein the position of the at least one unnatural amino acid is selected from K35, F42, K43, E62, and P65, wherein the residue positions correspond to positions 35, 42, 43, 62, and 65 as set forth in SEQ ID NO: 1; wherein the conjugating moiety is a water-soluble polymer; and wherein the modified IL-2 polypeptide comprises at least 80% sequence identity to SEQ ID NO: 1.
2. The modified IL-2 polypeptide of claim 1, wherein the position of the at least one unnatural amino acid is F42, wherein the residue position corresponds to position 42 as set forth in SEQ ID NO: 1.
3. The modified IL-2 polypeptide of claim 1, wherein the position of the at least one unnatural amino acid is K35, wherein the residue position corresponds to position 35 as set forth in SEQ ID NO: 1.
4. The modified IL-2 polypeptide of claim 1, wherein the position of the at least one unnatural amino acid is K43, wherein the residue position corresponds to position 43 as set forth in SEQ ID NO: 1.
5. The modified IL-2 polypeptide of claim 1, wherein the position of the at least one unnatural amino acid is E62, wherein the residue position corresponds to position 62 as set forth in SEQ ID NO: 1.
6. The modified IL-2 polypeptide of claim 1, wherein the position of the at least one unnatural amino acid is P65, wherein the residue position corresponds to position 65 as set forth in SEQ ID NO: 1.
7. The modified IL-2 polypeptide of any one of claims 1-6, wherein the at least one unnatural amino acid: • is a lysine analogue; or • comprises an aromatic side chain. - 1 2 6 - 20643611_1 (GHMatters) P114364.NZ
8. The modified IL-2 polypeptide of claim 7, wherein the at least one unnatural amino acid comprises N6-azidoethoxy-L-lysine (AzK), N6-propargylethoxy-L-lysine (PraK), BCN-L-lysine, norbornene lysine, TCO-lysine, methyltetrazine lysine, allyloxycarbonyllysine, p-acetyl-L-phenylalanine, p-azidomethyl-L-phenylalanine (pAMF), p-iodo-L-phenylalanine, m-acetylphenylalanine, p- propargyloxyphenylalanine, p-propargyl-phenylalanine, 3-methyl-phenylalanine, fluorinated phenylalanine, isopropyl-L-phenylalanine, p-azido-L-phenylalanine, p- acyl-L-phenylalanine, p-benzoyl-L-phenylalanine, p-bromophenylalanine, p-amino-L- phenylalanine, O-allyltyrosine, O-methyl-L-tyrosine, Oallyl-L-tyrosine, 4-propyl- L-tyrosine, phosphonotyrosine, L(2-naphthyl)alanine, 2-amino((2-((3- (benzyloxy)oxopropyl)amino)ethyl)selanyl)propanoic acid, or 2-amino (phenylselanyl)propanoic acid.
9. The modified IL-2 polypeptide of any one of claims 1-8, wherein the water-soluble polymer comprises polyethylene glycol (PEG), poly(propylene glycol) (PPG), copolymers of ethylene glycol and propylene glycol, poly(oxyethylated polyol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxyalkylmethacrylamide), poly(hydroxyalkylmethacrylate), poly(saccharides), poly(a-hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazolines (POZ), poly(N-acryloylmorpholine), or a combination thereof.
10. The modified IL-2 polypeptide of claim 9, wherein the water-soluble polymer comprises PEG.
11. The modified IL-2 polypeptide of claims 9 or 10, wherein the PEG has a weight- average molecular weight of from about 20 kDa to about 85 kDa.
12. The modified IL-2 polypeptide of any one of claims 9-11, wherein the PEG has a weight-average molecular weight of about 20 kDa, about 25 kDa, about 30 kDa, about 35 kDa, about 40 kDa, about 45 kDa, or about 50 kDa.
13. The modified IL-2 polypeptide of any one of claims 9-12, wherein the PEG has a weight-average molecular weight of about 30 kDa. 20643611_1 (GHMatters) P114364.NZ
14. The modified IL-2 polypeptide of any one of claims 1-13, wherein the conjugating moiety is covalently attached to the at least one unnatural amino acid of the modified IL-2 polypeptide through a linker.
15. The modified IL-2 polypeptide of claim 14, wherein the linker comprises a homobifunctional linker, a heterobifunctional linker, a cleavable or a non-cleavable dipeptide linker, a spacer, or a combination thereof.
16. The modified IL-2 polypeptide of any one of claims 1-15, wherein the modified IL-2 polypeptide comprises an N-terminal deletion.
17. The modified IL-2 polypeptide of any one of claims 1-15, wherein the modified IL-2 polypeptide comprises (i) the sequence of SEQ ID NO: 1 in which the position of the at least one unnatural amino acid is selected from K35, F42, K43, E62, and P65, wherein the residue positions correspond to positions 35, 42, 43, 62, and 65 as set forth in SEQ ID NO: 1 or (ii) the sequence of SEQ ID NO: 1 in which the position of the at least one unnatural amino acid is selected from K35, F42, K43, E62, and P65, wherein the residue positions correspond to positions 35, 42, 43, 62, and 65 as set forth in SEQ ID NO: 1 and having an N-terminal deletion, and wherein the modified IL-2 polypeptide optionally further comprises an additional mutation.
18. The modified IL-2 polypeptide of claim 16 or 17, wherein the N-terminal deletion comprises a deletion of the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, or 25 residues from the N-terminus, wherein the residue positions correspond to the positions as set forth in SEQ ID NO: 1.
19. The modified IL-2 polypeptide of any one of claims 1-16 and 18, wherein the modified IL-2 polypeptide comprises about 80%, 85%, or 90% sequence identity to SEQ ID NO: 1.
20. The modified IL-2 polypeptide of any one of claims 1-16 and 18, wherein the modified IL-2 polypeptide comprises about 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1.
21. The modified IL-2 polypeptide of any one of claims 1-20, wherein the modified IL-2 polypeptide is capable of expanding CD4+ helper cell, CD8+ effector naïve cell, 20643611_1 (GHMatters) P114364.NZ CD8+ effector memory cell, Natural Killer (NK) cell, or Natural Killer T (NKT) cell populations, or a combination thereof.
22. The modified IL-2 polypeptide of any one of claims 1-20, wherein the conjugating moiety or the unnatural amino acid impairs or blocks the binding of IL-2 with IL-2Ra.
23. The modified IL-2 polypeptide of any one of claims 1-20, wherein activation of CD4+ helper cell, CD8+ effector naïve cell, CD8+ effector memory cell, Natural Killer (NK) cell, or Natural Killer T (NKT) cell population via the IL-2Rß? complex by the modified IL-2 polypeptide retains significant potency of activation of said cell population relative to a wild-type IL-2 polypeptide.
24. The modified IL-2 polypeptide of claim 23, wherein the receptor signaling potency of the modified IL-2 polypeptide to the IL-2Rß? complex is higher than a receptor signaling potency of the wild-type IL-2 polypeptide to the IL-2Rß? complex.
25. The modified IL-2 polypeptide of claim 23, wherein the receptor signaling potency of the modified IL-2 polypeptide to the IL-2Rß? complex is lower than a receptor signaling potency of the wild-type IL-2 polypeptide to the IL-2Rß? complex.
26. The modified IL-2 polypeptide of any one of claims 1-20, wherein the modified IL-2 polypeptide exhibits a first receptor signaling potency to IL-2Rß? and a second receptor signaling potency to IL-2Raß?, and wherein the first receptor signaling potency is at least 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 50-fold, 100-fold, or 500-fold higher than the second receptor signaling potency.
27. The modified IL-2 polypeptide of claim 26, wherein the first receptor signaling potency of the modified IL-2 polypeptide is higher than a receptor signaling potency of a wild-type IL-2 polypeptide to the IL-2Rß?, and the second receptor signaling potency of the modified IL-2 polypeptide is lower than a receptor signaling potency of the wild-type IL-2 polypeptide to the IL-2Raß?.
28. A pharmaceutical composition comprising the modified IL-2 polypeptide of any one of claims 1-27, and a pharmaceutically acceptable excipient. 20643611_1 (GHMatters) P114364.NZ
29. The pharmaceutical composition of claim 28, wherein the pharmaceutical composition is formulated for systemic delivery.
30. The pharmaceutical composition of claim 28, wherein the pharmaceutical composition is formulated for parenteral administration.
31. Use of the modified IL-2 polypeptide of any one of claims 1-27 or the pharmaceutical composition of any one of claims 28-30 in the manufacture of a medicament for treating a proliferative disease or condition in a subject in need thereof.
32. The use of claim 31, wherein the proliferative disease or condition is a cancer.
33. The use of claim 32, wherein the cancer is a solid tumor cancer.
34. The use of claim 33, wherein the solid tumor cancer is bladder cancer, bone cancer, brain cancer, breast cancer, colorectal cancer, esophageal cancer, eye cancer, head and neck cancer, kidney cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, or prostate cancer.
35. The use of claim 32, wherein the cancer is a hematologic malignancy.
36. The use of claim 35, wherein the hematologic malignancy is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenstrom’s macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt’s lymphoma, non- Burkitt high grade B cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis.
37. The use of claim 31, wherein an additional therapeutic agent is to be administered.
38. The use of claim 37, wherein the medicament and the additional therapeutic agent are to be administered simultaneously. 20643611_1 (GHMatters) P114364.NZ
39. The use of claim 37, wherein the medicament and the additional therapeutic agent are to be administered sequentially.
40. The use of claim 39, wherein the medicament is to be administered prior to the additional therapeutic agent.
41. The use of claim 39, wherein the medicament is to be administered after the administration of the additional therapeutic agent.
42. The use of any one of claims 31-41, wherein in the modified IL-2 polypeptide the position of the at least one unnatural amino acid is P65, wherein the residue position corresponds to position 65 as set forth in SEQ ID NO: 1.
43. An in vitro or ex vivo method of expanding a CD4+ helper cell, CD8+ effector naïve cell, CD8+ effector memory cell, Natural Killer (NK) cell, or Natural Killer T (NKT) cell population, comprising: contacting a cell population comprising CD4+ helper cells, CD8+ effector naïve cells, CD8+ effector memory cells, Natural Killer (NK) cells, and/or Natural Killer T (NKT) cells with the modified IL-2 polypeptide of any one of claims 1-26, or the pharmaceutical composition of any one of claims 27-29, for a time sufficient to induce formation of a complex with an IL-2Rß?, thereby stimulating the expansion of the CD4+ helper cells, CD8+ effector naïve cells, CD8+ effector memory cells, Natural Killer (NK) cells, and/or Natural Killer T (NKT) cells of the population.
44. The method of claim 43, wherein the modified IL-2 polypeptide or the pharmaceutical composition expands CD4+ T regulatory (Treg) cells by less than 20%, 15%, 10%, 5%, or 1%.
45. The method of claim 43, wherein the modified IL-2 polypeptide or the pharmaceutical composition does not expand CD4+ Treg cells in the cell population.
46. The method of claim 43, wherein the cell population comprises Teff cells and Treg cells, and the ratio of the Teff cells to Treg cells in the cell population after contacting the cell population with the modified IL-2 polypeptide or the pharmaceutical composition is about or at least 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 20:1, 50:1, or 100:1. 20643611_1 (GHMatters) P114364.NZ
47. The method of claim 43, wherein the method is an in vitro method.
48. The method of claim 43, wherein the method is an ex vivo method.
49. The method of any one of claims 43-48, wherein the cell population is from a human subject. 20643611_1 (GHMatters) P114364.NZ
NZ761430A 2018-08-03 Cytokine conjugates for the treatment of proliferative and infectious diseases NZ761430B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762540781P 2017-08-03 2017-08-03
PCT/US2018/045257 WO2019028419A1 (en) 2017-08-03 2018-08-03 Cytokine conjugates for the treatment of proliferative and infectious diseases

Publications (2)

Publication Number Publication Date
NZ761430A NZ761430A (en) 2024-03-22
NZ761430B2 true NZ761430B2 (en) 2024-06-25

Family

ID=

Similar Documents

Publication Publication Date Title
JP2020529977A5 (en)
JP2020529976A5 (en)
JP7457642B2 (en) Protein antigens and uses thereof
TWI837869B (en) Neoantigens and methods of their use
CN109152830B (en) Core/shell structural platform for immunotherapy
AU2006259221B2 (en) Multivalent entrain-and-amplify immunotherapeutics for carcinoma
JP2018505139A (en) Anti-CD70 chimeric antigen receptor
KR20230004682A (en) Human interleukin-2 conjugates biased against the interleukin-2 receptor beta gamma c dimer and conjugated to non-peptide water soluble polymers
EP1073733B1 (en) MUTATED PEPTIDE COMPOUNDS, DERIVED FROM hsp70, USEFUL IN CANCER IMMUNOTHERAPY
Patel et al. Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth
JP2008543315A (en) Methods and compositions for eliciting a multivalent immune response against dominant and subdominant epitopes expressed on cancer cells and tumor stroma
ES2362715T3 (en) COMPOSITIONS AND METHODS FOR DIVERTIC CELL-BASED IMMUNOTHERAPY.
NZ761430B2 (en) Cytokine conjugates for the treatment of proliferative and infectious diseases
NZ761430A (en) Cytokine conjugates for the treatment of proliferative and infectious diseases
CN101426532A (en) In vivo cell surface engineering
CN101690801B (en) Application of interleukin-1 receptor antagonist and medicinal composition thereof
US20180161433A1 (en) Size tunable microbial mimetics for immunotherapy of thyroid carcinomas and solid tumors
EP4054644A1 (en) Interleukin 10 conjugates and uses thereof
RU2022100330A (en) PEPTIDE DERIVED FROM DEPDC1 AND VACCINE CONTAINING IT
RU2022132620A (en) CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
NZ761434B2 (en) Cytokine conjugates for the treatment of autoimmune diseases
WO2024002363A1 (en) Il-2 polypeptides and methods of use
Giordano et al. New dimensions in cancer biology and therapy
JPWO2020047176A5 (en)
US20220143161A1 (en) Mrna vaccine